Pre-op surgery
3 February 2021

The $89 bln health group is pressing on with a plan to spin off its consumer drugs unit. But its shares are depressed by slow growth and competition in the core pharma division, requiring risky investment and M&A. A dividend chop at least gives CEO Emma Walmsley some elbow room.